Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Jun 26, 2014; 4(2): 59-72
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.59
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.59
MicroRNAs in lung cancer
Pooja Joshi, Justin Middleton, Young-Jun Jeon, Michela Garofalo, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States
Michela Garofalo, Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, United Kingdom
Author contributions: Joshi P and Middleton J contributed equally to the manuscript and designed figures; Jeon YJ contributed to the manuscript and figure design; Garofalo M developed the concept and edited.
Correspondence to: Michela Garofalo, PhD, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University, 460 West 12th Street, BRT 992, Columbus, OH 43210,United States. michela.garofalo@cruk.manchester.ac.uk
Telephone: +1-614-6883418 Fax: +1-614-2924097
Received: November 28, 2013
Revised: January 23, 2014
Accepted: March 17, 2014
Published online: June 26, 2014
Revised: January 23, 2014
Accepted: March 17, 2014
Published online: June 26, 2014
Core Tip
Core tip: Lung cancer is a prolific and high mortality disease, with few effective treatments. MicroRNAs have a role in the biogenesis and maintenance of lung cancer, with oncogenic and tumor suppressive effects. They are also a significant factor in resistance to current forms of therapy. There is evidence that microRNAs will be useful as diagnostic and predictive biomarkers in the future and, if delivery challenges can be overcome, they may become integrated into treatments.